Mohan Paul Singh Ishar
Maharaja Ranjit Singh Punjab Technical University, India
Prof. Mohan Paul Singh Ishar, an alumnus of Indian Institute of Technology, Delhi, is presently serving as Vice Chancellor, Maharaja Ranjit Singh Punjab Technical University, Bathinda (Punjab) India. With more than 1500 citations, 120 papers in reputed journals and 70 presentations in conferences, he is leading a research team focusing on Synthetic Organic and Medical Chemistry; the Design Synthesis and Evaluation of Biologically Active Compounds, Anti-Cancer Drugs and Anti-Microbial Agents, Allene Chemistry, Steroid Chemistry and Organic Photo Chemistry. and also serving as an editorial board member of repute.
The systematic discovery of new drugs, also called “Drug Designing”, involves envisioning, preparation and systematic evaluation of specific new molecules leading to more efficient drug discovery. A modern drug designing research is a frontier area which requires inputs from diverse disciplines such as Natural product chemistry, Synthetic chemistry, Computational chemistry, Spectroscopic techniques- in particular NMR and X-ray crystallography, Biochemistry, Physiology, Genomic technologies, Bioinformatics, Molecular biology, Microbiology, Pharmacology, etc. A number of approaches are being adopted for discovery of new “lead” structures. Despite tremendous advancements made in synthetic methodologies, natural products continue to be the most consistent source of new exotic molecular frameworks fore drug discovery. Despite tremendous advancements in identification of new targets for chemotherapeutic intervention in fight against cancer and combination regimens of available anti-cancer drugs, problem of adverse effects and developing resistance of cancer cells to drugs have made many chemotherapeutic regimens ineffective. Therefore, the search for novel targets for anticancer drugs and more effective chemotherapeutic agents for the treatment of cancer is highly desired. The presentation enlists modern targets for anticancer drug designing program and includes examples form our own work on design, synthesis and systematic evaluation of some chromone and β-ionone based cytotoxic agents obtained through environmentally benign synthetic protocols.